Osteoblast/Osteoclast Development and Function in Osteogenesis Imperfecta - Osteogenesis Imperfecta - page 47

alleles in osteogenesis imperfecta type I cell strains. Am J Hum
Genet 1996;59(4):799-809.
[60] Superti-Furga A, Raghunath M, Pistone FM, Romano C,
Steinmann B. An intronic deletion leading to skipping of exon
21 of COL1A2 in a boy with mild osteogenesis imperfecta.
Connect Tissue Res 1993;29(1):31-40.
[61] Yang W, Battineni ML, Brodsky B. Amino acid sequence envi-
ronment modulates the disruption by osteogenesis imperfecta
glycine substitutions in collagen-like peptides. Biochemistry
1997;36(23):6930-5.
[62] Byers PH, Steiner RD. Osteogenesis imperfecta. Annu Rev Med
1992;43:269-82.
[63] Dombrowski KE, Vogel BE, Prockop DJ. Mutations that alter
the primary structure of type I procollagen have long-range
effects on its cleavage by procollagen N-proteinase. Biochemistry
1989;28(17):7107-12.
[64] Kobayashi K, Hata R, Nagai S, Niwa J, Hoshino T. Direct
visualization of affected collagen molecules synthesized by
cultured ibroblasts from an osteogenesis imperfecta patient.
Biochem Biophys Res Commun 1990;172(1):217-22.
[65] Ishikawa Y, Wirz J, Vranka JA, Nagata K, Bachinger HP.
Biochemical characterization of the prolyl 3-hydroxylase 1.car-
tilage-associated protein.cyclophilin B complex. J Biol Chem
2009;284(26):17641-47.
[66] Amor IM, Rauch F, Gruenwald K, Weis M, Eyre DR, Roughley P,
et al. Severe osteogenesis imperfecta caused by a small in-frame
deletion in CRTAP. Am J Med Genet A 2011;155A(11):2865-70.
[67] Morello R, Bertin TK, Chen Y, Hicks J, Tonachini L, Monticone
M, et al. CRTAP is required for prolyl 3-hydroxylation and
mutations cause recessive osteogenesis imperfecta. Cell
2006;127(2):291-304.
[68] Barnes AM, Chang W, Morello R, Cabral WA, Weis M, Eyre DR,
et al. Deiciency of cartilage-associated protein in recessive lethal
osteogenesis imperfecta. N Engl J Med 2006;355(26):2757-64.
[69] Valli M, Barnes A, Gallanti A, Cabral W, Viglio S, Weis M,
et al. Deiciency of CRTAP in non-lethal recessive osteogenesis
imperfecta reduces collagen deposition into matrix. Clin Genet
2012;82(5):453-9.
[70] Takagi M, Ishii T, Barnes AM, Weis M, Amano N, Tanaka M,
et al. A novel mutation in LEPRE1 that eliminates only the
KDEL ER-retrieval sequence causes non-lethal osteogenesis
imperfecta. PloS One 2012;7(5):e36809.
[71] Willaert A, Malfait F, Symoens S, Gevaert K, Kayserili H,
Megarbane A, et al. Recessive osteogenesis imperfecta caused
by LEPRE1 mutations: clinical documentation and identiica-
tion of the splice form responsible for prolyl 3-hydroxylation.
J Med Genet 2009;46(4):233-41.
[72] van Dijk FS, Nesbitt IM, Zwikstra EH, Nikkels PG, Piersma SR,
Fratantoni SA, et al. PPIB mutations cause severe osteogenesis
imperfecta. Am J Hum Genet 2009;85(4):521-7.
[73] Pyott SM, Schwarze U, Christiansen HE, Pepin MG, Leistritz DF,
Dineen R, et al. Mutations in PPIB (cyclophilin B) delay type I
procollagen chain association and result in perinatal lethal to
moderate osteogenesis imperfecta phenotypes. Hum Mol Genet
2011;20(8):1595-609.
[74] Barnes AM, Cabral WA, Weis M, Makareeva E, Mertz EL,
Leikin S, et al. Absence of FKBP10 in recessive type XI osteo-
genesis imperfecta leads to diminished collagen cross-linking
and reduced collagen deposition in extracellular matrix. Hum
Mutat 2012;33(11):1589-98.
[75] Kelley BP, Malfait F, Bonafe L, Baldridge D, Homan E, Symoens S,
et al. Mutations in FKBP10 cause recessive osteogenesis imperfecta
and Bruck syndrome. J Bone Miner Res 2011;26(3):666-72.
[76] Setijowati ED, van Dijk FS, Cobben JM, van Rijn RR,
Sistermans EA, Faradz SM, et al. A novel homozygous 5 bp

deletion in FKBP10 causes clinically Bruck syndrome in an
Indonesian patient. Eur J Med Genet 2012;55(1):17-21.
[77] Shaheen R, Al-Owain M, Faqeih E, Al-Hashmi N, Awaji A,
Al-Zayed Z, et al. Mutations in FKBP10 cause both Bruck syn-
drome and isolated osteogenesis imperfecta in humans. Am J
Med Genet A 2011;155A(6):1448-52.
[78] Steinlein OK, Aichinger E, Trucks H, Sander T. Mutations
in FKBP10 can cause a severe form of isolated Osteogenesis
imperfecta. BMC Med Genet 2011;12:152.
[79] Venturi G, Monti E, Dalle Carbonare L, Corradi M, Gandini A,
Valenti MT, et al. A novel splicing mutation in FKBP10 causing
osteogenesis imperfecta with a possible mineralization defect.
Bone 2012;50(1):343-9.
[80] Christiansen HE, Schwarze U, Pyott SM, AlSwaid A, Al Balwi
M, Alrasheed S, et al. Homozygosity for a missense mutation
in SERPINH1, which encodes the collagen chaperone protein
HSP47, results in severe recessive osteogenesis imperfecta. Am
J Hum Genet 2010;86(3):389-98.
[81] Puig-Hervas MT, Temtamy S, Aglan M, Valencia M, Martinez-
Glez V, Ballesta-Martinez MJ, et al. Mutations in PLOD2 cause
autosomal-recessive connective tissue disorders within the
Bruck syndrome-Osteogenesis imperfecta phenotypic spec-
trum. Hum Mutat 2012;33(10):1444-9.
[82] Lapunzina P, Aglan M, Temtamy S, Caparros-Martin JA,
Valencia M, Leton R, et al. Identiication of a frameshift muta-
tion in Osterix in a patient with recessive osteogenesis imper-
fecta. Am J Hum Genet 2010;87(1):110-4.
[83] Venturi G, Gandini A, Monti E, Dalle Carbonare L, Corradi M,
Vincenzi M, et al. Lack of expression of SERPINF1, the gene
coding for pigment epithelium-derived factor, causes progres-
sively deforming osteogenesis imperfecta with normal type I
collagen. J Bone Miner Res 2012;27(3):723-8.
[84] Akiyama T, Dass CR, Shinoda Y, Kawano H, Tanaka S, Choong
PF. PEDF regulates osteoclasts via osteoprotegerin and RANKL.
Biochem Biophys Res Commun 2010;391(1):789-94.
[85] Holbrook KA, Byers PH, Pinnell SR. The structure and function
of dermal connective tissue in normal individuals and patients
with inherited connective tissue disorders. Scan Electron
Microsc 1982(Pt 4):1731-44.
[86] Smith R, Francis MJ, Bauze RJ. Osteogenesis imperfecta. A clin-
ical and biochemical study of a generalized connective tissue
disorder. Q J Med 1975;44(176):555-73.
[87] Hansen B, Jemec GB. The mechanical properties of skin in
osteogenesis imperfecta. Arch Dermatol 2002;138(7):909-11.
[88] Fedarko NS. The biology of aging and frailty. Clin Geriatr Med
2011;27(1):27-37.
[89] Penttinen RP, Lichtenstein JR, Martin GR, McKusick VA.
Abnormal collagen metabolism in cultured cells in osteogen-
esis imperfecta. Proc Natl Acad Sci USA 1975;72(2):586-9.
[90] Barsh GS, Byers PH. Reduced secretion of structurally abnor-
mal type I procollagen in a form of osteogenesis imperfecta.
Proc Natl Acad Sci USA 1981;78(8):5142-6.
[91] Barsh GS, David KE, Byers PH. Type I osteogenesis imperfecta:
a nonfunctional allele for pro alpha 1 (I) chains of type I procol-
lagen. Proc Natl Acad Sci USA 1982;79(12):3838-42.
[92] Fraser J, Lancaster GA, Scriver CR. Secreted collagen ratios in
normal human and osteogenesis imperfecta skin ibroblasts.
Connect Tissue Res 1983;11(1):57-67.
[93] Deak SB, Nicholls A, Pope FM, Prockop DJ. The molecular defect
in a nonlethal variant of osteogenesis imperfecta. Synthesis of
pro-alpha 2(I) chains which are not incorporated into trimers of
type I procollagen. J Biol Chem 1983;258(24):15192-97.
[94] Bateman JF, Mascara T, Chan D, Cole WG. Abnormal type I
collagen metabolism by cultured ibroblasts in lethal perinatal
osteogenesis imperfecta. Biochem J 1984;217(1):103-15.